



Update on chikungunya vaccines

Susan Hills MBBS MTH
CDC Lead, Chikungunya Vaccines Work Group
Arboviral Diseases Branch
Division of Vector-Borne Diseases
Fort Collins, Colorado

ACIP Meeting, June 26, 2024

Virus-like particle chikungunya vaccine

- Manufactured by Bavarian Nordic
- Submission of BLA to FDA completed on June 17, 2024
- Licensure possible first half of 2025
- Intended age group is adolescents and adults aged ≥ 12 years
- Single dose schedule

Live attenuated chikungunya vaccine

- Manufactured by Valneva as IXCHIQ
- Licensed November 9, 2023
- Age group currently adults ≥ 18 years
- Single dose schedule

